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Abstract
Background: Since the mid-1990s, there have been growing efforts to prevent cervical cancer in less-developed
countries through the development of innovative screening approaches such as visual inspection of the cervix
associated with same day management of cervical lesions with cryotherapy or loop electrosurgical excision
procedure (LEEP). In the past, promising cancer screening interventions have been widely promoted despite
incomplete evidence, only to become the subject of intense controversies about ensuing net health benefit.
Because the efficacy and effectiveness of the new protocols for global cervical cancer screening have not been
well characterized yet, and as a contribution to the evaluation of the balance between the benefits and risks of
these protocols, we reviewed the literature on the safety of cryotherapy and LEEP for cervical intraepithelial
neoplasia (CIN) in low- and middle-income countries.
Methods: We searched 12 databases (Medline, Google Scholar, Scopus, Cochrane Library, Web of Science, OCLC,
PAIS International Database, WHO Global Health Library, CINAHL, Science.gov, NYAM Grey Literature Report, and
POPLINE) for original research published between January 1995 and April 2009. Both peer-reviewed publications
and items of “grey” literature were retrieved; no language restriction was applied. We calculated the median
(minimum, maximum) reported rate for each harm considered. Because of limitations and heterogeneity in the
data, no formal meta-analysis was performed.
Results: The search identified 32 articles that reported safety data from 24 cryotherapy and LEEP studies. The
combined sample consisted of 6,902 women treated by cryotherapy and 4,524 women treated by LEEP. Most
studies were conducted in reference or research settings in Asia and Africa. Short-term harms of cryotherapy and
LEEP appeared to be similar to those described in the literature from high-income countries. Information was
sparse on HIV-related harms and long-term reproductive outcomes of treatment.
Conclusions: When performed in resource-limited settings by qualified providers, cryotherapy and LEEP are not
associated with excess harm. However, available data are insufficient to propose fully evidence-based protocols for
routine screening of HIV-infected women and women of reproductive age.
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In resource-limited countries where cervical cancer is
typically the most common cause of premature death
among middle-aged women, an estimated 230,000
women die each year from invasive cervical cancer
(ICC) [1,2]. In many parts of the developing world, age-
standardized incidence rates of ICC are ≥ 4-fold higher
than in North America and Western Europe, reaching
values in excess of 30-to-50 per 100,000 women in large
areas of sub-Saharan Africa, Latin America, the Carib-
bean, South Asia and Oceania [1].
Whereas cervical cancer burden in industrialized
countries decreased sharply after the widespread intro-
duction of effective cytological screening programs,
these favourable results have not been replicated in the
developing world. In low-income countries resources
and infrastructure proved insufficient to offer quality
Pap smear screening to more than a small fraction of
adult women and high rates of loss to follow-up asso-
ciated with multi-visit screening protocols further ham-
pered success. Hence, with evidence suggesting that
human papillomavirus (HPV) vaccine will not substitute
for secondary prevention [3], attention has been redir-
ected toward the development of novel and simple cer-
vical cancer screening approaches more suitable for use
in resource-poor settings. These efforts have led to the
emergence of screening of middle-aged women by
means of visual inspection of the cervix (after applica-
tion of acetic acid or Lugol’s iodine), or high-risk HPV
DNA testing, coupled with immediate or shortly
deferred management of abnormalities, as potentially
viable and cost-effective strategies to reduce ICC inci-
dence in less-developed countries [4-6].
This encouraging advance should be viewed with the
understanding that cancer screening has often been con-
troversial. Much debate in particular has surrounded the
tendency for the medical and public health community
to aggressively promote new screening interventions at
the population level before obtaining solid evidence that
the benefits of early detection reasonably outweigh the
harms [7-9]. According to the International Agency for
Research on Cancer (IARC [10]), pilot cervical cancer
screening programs are being implemented in more
than 40 developing countries. Although research find-
ings generally support the appropriateness of low-tech-
nology cervical cancer screening, important questions
remain in particular in terms of screening test, defini-
tion of target populations, long-term quality control,
and human resource commitment [11-14]. A major
shortcoming of “screen-and-treat” approaches without
tissue diagnosis is that up to 80%-90% of women who
receive treatment following an abnormal primary
screening result are free of CIN 2 or worse [15,16].
A substantial proportion of these women are at low risk
for progression to high-grade lesion or ICC, and there-
fore do not truly benefit from therapy. Cumulatively,
potential harms experienced by screening participants
are not only detrimental in themselves; they could also
negatively affect future screening coverage–a key deter-
minant of program cost-effectiveness [6]. Finally, there
are at least theoretical reasons to fear that minor
adverse effects of treatment may evolve into severe com-
plications more frequently in low- than in high-income
countries, since women living in less affluent settings
are more likely to be affected by comorbidities (e.g.,
HIV or anaemia) and to lack timely access to adequate
medical care. For these reasons, a crucial precondition
for the global scale-up of single-visit screening programs
is the guarantee that acceptable safety levels are
achieved under routine conditions of implementation.
Looking at pilot studies in low-resource settings,
cryotherapy (i.e., freezing of cervical lesion by applica-
tion of liquid nitric oxide or carbon dioxide [17]) per-
formed by mid-level providers has been used for the
management of up to 85%-90% of abnormalities
detected by screening [18,19]. Typically, women ineligi-
ble for cryotherapy were referred for further evaluation
and therapy by loop electrosurgical excision procedure
(LEEP [20]). In 2003, the Alliance for Cervical Cancer
Prevention (ACCP) reviewed evidence published in
1955-2001 on the safety of cryotherapy for the manage-
ment of CIN [21]. Most of the studies included in the
review were conducted in high-income countries and
focused on treatments performed by high-level providers
under colposcopic guidance. To complement this work,
we report here on the results of a systematic review of
the literature published between 1995 and 2009 on the
safety of cryotherapy and LEEP for the management of
cervical lesions of any grade in low- and middle-income
countries.
Methods
Search strategy and selection criteria
We searched Medline (PubMed), Google Scholar, Sco-
pus (Elsevier), the Cochrane Library, Web of Science,
OCLC (Paper First and Proceedings First), PAIS Inter-
national Database (EBSCO), WHO Global Health
Library, CINAHL, Science.gov, the New York Academy
of Medicine Grey Literature Report, and POPLINE for
single reports, abstracts and other “grey literature” pub-
lished in any language between January 1995 and April
2009. We chose 1995 for our starting point since the
modern concept of low-technology single-visit screening
for cervical cancer emerged around that time. With the
support of a medical librarian, we combined more than
20 key search terms (Additional file 1: search algorithm
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women with cervical intraepithelial neoplasia of any
grade were treated with either cryotherapy or LEEP.
For the main search, two reviewers independently
judged each publication for eligibility by reviewing the
title and abstract. Discrepancies were resolved through
discussion between reviewers. References were excluded
at this stage if CIN therapy was mentioned only inciden-
tally or if the research was conducted in a high-income
country [22]. No restriction was imposed by study
design. The references of the articles obtained from the
initial search were manually screened for additional stu-
dies. We read the full text of each citation that reported
original clinical data and appeared to include informa-
tion on treatment by cryotherapy or LEEP.
Data abstraction and quality assessment
During the main search, two reviewers independently
used a pretested form to extract the following data: year
of publication; country; study design; population, indica-
tions to treatment; treatment setting and characteristics;
follow-up; and adverse outcomes. Disagreements among
reviewers were arbitrated by a third investigator. Quality
of safety reporting was based on the following four cri-
teria: (1) recruitment completeness among members of
a clearly-defined cohort; (2) report of explicit definitions
that allow for reproducible ascertainment of two or
more harms; (3) assessment of patients status within
seven days to one month of treatment; and (4) attrition
rate ≤ 20% until first follow-up assessment [21,23].
Analysis
Because the methods and quality of harm ascertainment
varied considerably from one study to the other, we
only estimated the minimum, median, and maximum
rates of each adverse outcome across studies.
Results
The literature search produced 32 articles (31 publica-
tions and 1 conference report; Figure 1) that reported
on non-overlapping harms of cryotherapy, LEEP, or
both in 24 studies fulfilling the inclusion criteria (Addi-
tional files 2 and 3). For five studies, non-overlapping
safety data were found in more than one article.
Study characteristics
Eight studies provided data on harms of cryotherapy [24,
(25,26),27-32], 13 on harms of LEEP [19,33-47], and 3
on harms of both cryotherapy and LEEP [(48-50),
(51,52),(53,54)] (Additional files 2 and 3).
Indication for treatment was a biopsy- or colposcopi-
cally-confirmed diagnosis of CIN in 17 studies (71%)
and an abnormal screening test result without further
diagnosis work-up ("screen-and-treat” approach) in 6
studies (25%); 1 study (4%) included women with either
indication for treatment. Age of participants was
reported for 17 of the 24 studies and ranged from 13 to
96 years (Additional files 2 and 3); most women were in
their late 20s to early 50s. Eleven studies were from
Asia, 7 from Africa, 4 from Latin America, and 2 from
Eastern Europe. Five (21%) studies were randomized
controlled trials, 12 (50%) were prospective cohort stu-
dies, and 7 (29%) were retrospective case series. Median
sample size was 574 for cryotherapy and 149 for LEEP.
In total, the review included evidence on 6,902 women
who underwent cryotherapy and 4,524 women who
underwent LEEP. Per our criteria, study quality for
harm assessment was low: only 5 studies (21%) met 3 or
more criteria (Additional files 2 and 3).
Treatment
Contraindications to treatment were discussed in all of
the cryotherapy studies and in 14 (88%) of the LEEP
studies (Table 1). Community outreach was the prime
method of enrollment for studies that focused on
cryotherapy (64%). In LEEP studies, participants were
typically recruited among outpatients of gynecology
clinics or tertiary care centers (63%). Treatment was
offered in fixed or mobile primary care centers in
8 (73%) of the cryotherapy studies, and in gynecology
clinics or tertiary care centers in 12 (75%) of the LEEP
studies (missing information, 1 study). LEEP was vir-
tually always performed by a doctor in a single health
center whereas cryotherapy was commonly performed
by mid-level care providers (primarily nurses) located in
more than one health facility. Information on number of
operators was inconsistently reported, although
cryotherapy appears to have been more frequently per-
formed by multiple operators than LEEP. As expected,
local anesthesia (general anesthesia in [44]) was used to
control pain during LEEP, but not during cryotherapy.
Information on prophylactic antibiotic therapy was
inconsistently reported; routine antibiotic therapy was
described in 4 (36%) cryotherapy studies and 3 (19%)
LEEP studies.
Technical factors potentially influencing safety
Ten cryotherapy studies reported that a double-freeze
technique had been used in all, or most, of the patients
[24,25,27-31,48,51,54]; 6 specified the nature of the refrig-
erant employed (nitric oxide, 4 [24,29,48,51]; carbon diox-
ide, 2 [25,31]); and 7 reported information on the type
[24,27,30,48,51,54] and the size [24,25,27,30,48,51] of the
cryoprobe selected. For LEEP, loop size was adapted
to the size of the lesion in 8 studies [33,37,39-41,44,47,52]
(fixed 20 mm loop-size [46]; unreported size [19,38,
42,43,45,49,52]). In 7 studies, cone depth was ≥ 10 mm in
most patients [33,37,39,40,44,45,47] (unreported depth
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Cryotherapy* LEEP*
n (%) n (%)
Indications/contraindications**
Restrictions based on lesion size and extension 8 (72.7) 0 (0.0)
Transformation zone entirely visible 6 (54.5) 2 (12.5)
No evidence of invasive disease 6 (54.5) 5 (31.3)
No history of screening or treatment for CIN 7 (63.6) 2 (12.5)
No gynecologic abnormality
† 4 (36.4) 1 (6.3)
No severe cervicitis 1 (9.1) 2 (12.5)
Restrictions for pregnant women
†† 6 (54.5) 3 (18.8)
Contraindication to cryotherapy 0 (0.0) 5 (31.3)
Enrollment**
Community outreach 7 (63.6) 4 (25.0)
Primary care/local health centers 3 (27.3) 1 (6.3)
Gynecologic clinic/tertiary care 3 (27.3) 10 (62.5)
Not reported 0 (0.0) 1 (6.3)
Type of treatment center**
Gynecologic clinic/tertiary care 4 (36.4) 12 (75.0)
District hospital 2 (18.2) 2 (12.5)
Primary care center/mobile unit 8 (72.7) 1 (6.3)
Not reported 1 (9.1) 1 (6.3)
Number of treatment centers
One 5 (45.5) 16 (100)
Two or more 5 (45.5) 0 (0)
Not reported 1 (9.1) 0 (0)
Operator
Gynecologist, surgeon 1 (9.1) 4 (25.0)
Doctor, general practitioner 2 (18.2) 4 (25.0)
Nurse, “less qualified personnel” 5 (45.5) 1 (6.3)
Not reported 3 (27.3) 7 (43.8)
Number of operators
One 1 (9.1) 1 (6.3)
Two to five 1 (9.1) 5 (31.3)
Six or more 5 (45.5) 0 (0)
Not reported 4 (36.4) 10 (62.5)
Control of pain
No specific measure/Non-narcotic analgesics as needed 5 (45.5) 0 (0.0)
Local anesthesia 0 (0.0) 12 (75.0)
General anesthesia 0 (0.0) 1 (6.3)
Not reported 6 (54.5) 3 (18.8)
Antibiotherapy (pre-treatment)
Signs of cervicitis or STD 3 (27.3) 2 (12.5)
All women 4 (36.4) 3 (18.8)
Not reported 4 (36.4) 11 (68.8)
*Cryotherapy, 11 studies; LEEP, 16 studies.
**Total percent add to more than 100%, because some studies are represented in more than one item category.
†Abnormalities such as polyp or cervical atrophy, for instance.
††Different gestational ages across studies.
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current in 5 studies [33,37,41,44,47] and in cutting mode
in 2 studies [45,54]; (mode unreported [19,38-40,
42,43,47,49,52]). Finally, fulguration of the wound (± appli-
cation of Monsel’s solution) to provide hemostatis was
undertaken routinely in 10 studies [33,37-40,44-46,51,54]
and as needed in 2 [41,47] (unreported [19,42,43,52]).
Pain
I n f o r m a t i o no np a i na n dc r a m p i n gw a sp r o v i d e di n1 0
cryotherapy studies [24,26,27,29-32,48,51,54] and 4
LEEP studies [35,38,49,54] (Additional file 4). It was
generally unclear whether the patients’ or the providers’
perceptions were recorded. Mild-to-moderate pain dur-
ing or immediately after treatment was reported by
nearly one third of women who underwent cryotherapy
and by less than 5% of women who underwent LEEP
(severe pain: 1%-4%). Longer lasting pain, or pain asso-
ciated with the next menses, was common and docu-
mented considerably more often after LEEP (median,
67%; mean duration, 1-to 2-days [32]) than after
cryotherapy (median, 9%).
Vaginal discharge
Nine cryotherapy studies [24,26,29-32,48,51,54] and 5
LEEP studies [35,38,43,49,54] assessed the occurrence of
vaginal discharge post-treatment. Perhaps reflecting the
lack of standard method of assessment for mild side
effects, rates of watery discharge after cryotherapy varied
considerably across studies (9% to 92%; median, 65%)
compared to rates of offensive or disconcerting discharge
(1% to 11%, except in [54]; Additional file 4). Virtually
all women (79% to 100%) who underwent LEEP noted
some form of vaginal discharge. Rarely evaluated, dura-
tion of discharge ranged from one to three weeks in one
cryotherapy study [31] and averaged 14 ± 4.6 days in
one LEEP study [35]. No study attempted to measure
the amount of discharge.
Bleeding
Bleeding was an adverse outcome reported in all the
studies reviewed, except two [28,31]. Among women
treated with cryotherapy, intraoperative or immediate
postoperative bleeding was uncommon (<2%; Additional
file 4); slight delayed bleeding occurred in up to 10% to
40% of women, in particular in association with menses;
and hemorrhage requiring hospitalization or transfusion
was documented in only 1 study (1 of 949 women; 0.1%
[29]). In contrast, bleeding was frequent and sometimes
severe among women treated with LEEP. Typically,
uncomplicated post-LEEP bleeding was experienced by
all women for 3-to-4 days on average. One LEEP study
reported that clinically significant early bleeding
occurred in 2% of women [54]; whereas others indicated
that application of Monsel’s solution or electrocautery
were needed to control hemorrhage in up to 3.3% of
women during the first 24 hours post-treatment
[19,33,40] and in 1.5% to 5.2% of women during the fol-
lowing days and weeks [33,37,40,41,45,46,49]. Three stu-
dies reported that suture to control bleeding or
transfusion had been necessary in up to 0.8% of women
[33,38,52]. Finally, 2 studies mentioned that hysterect-
omy had been required to control postoperative bleed-
i n gi ns o m ep a t i e n t s .I nap r e l i m i n a r yr e p o r to ft h e
Osmanabad screening project in India [50], Sankaranar-
ayanan and coll. indicated that hysterectomy was per-
formed to manage hemorrhage in 1 woman out of the
first 50 treated by LEEP whereas no other instance of
emergency hysterectomy was recorded in the next 1090
women who received LEEP through the program (over-
all rate, 0.09% [49]). In a Chinese series of patients who
underwent hysterectomy within 6 months of LEEP for
CIN, hysterectomy was motivated by postoperative
hemorrhage of over 500 ml in 2 women out of 73.
Assuming that 5 percent of all the women treated by
L E E Ph a dah y s t e r e c t o m ya sad e f i n i t i v ec u r ef o rC I N
(information not provided), 0.14% of all LEEP treat-
ments were followed by an emergency hysterectomy.
Infection
Infectious complications were discussed in 7 cryotherapy
and 10 LEEP studies (Additional file 4). Cervical tender-
ness, fever, or wound infection requiring antibiotherapy
were documented in 0.0% to 2.6% of women treated
with cryotherapy [25,31,48,51,54] and 0.0% to 10.0%
(median, 1.2%) of women treated with LEEP [19,33,
38-40,44,46,47,49,54]. Pelvic inflammatory disease was
rare after both cryotherapy (0.0% to 0.1%) [24,25,
30,48,51] and LEEP (0.0% to 0.7%) [38,40,44,47,49].
Other short-term adverse outcomes
Accidental thermic lesions of the vaginal wall occurred
in 0.1% to 0.8% of women during cryotherapy (freezing)
[28,48,51] and in 0.4% to 4.4% of women during LEEP
(burning [38,49]; Additional file 4). Sidewall vaginal
lacerations during LEEP was a reported cause of intrao-
perative bleeding requiring suture hemostasis in one
study (0.3% of women) [19]. No bladder or bowel inju-
ries were noted in any LEEP study, even though several
accounts of such complications have been documented
in high-income countries [55,56]. Minor spontaneously-
resolving complications of local anesthesia were noted
in 2 LEEP studies after submucosal infiltration of 2%
lidocaine with 1:80,000 epinephrine (hypertension
among 26% [47] - and uncontrollable trembling of the
lower extremities among 0.3% of women [19]). In one
cryotherapy study [29], 25% of women presented at
their 1-month follow-up visit with a new troubling
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group, 10%). Unscheduled visits were documented in
4.4% to 9.7% of women in 3 cryotherapy studies
[27,29,30] and in 5.6% of women in one LEEP study
[43] (Additional file 4). Among women who had under-
gone cryotherapy, the visit led to the ambulatory treat-
ment of a complication in 0.0% to 2.2% of women
[27,30] and to hospital admission in 0.0% to 0.2% of
women [24,29,30,48,51]. Five studies, 3 of cryotherpy
[27,30,51] and 2 of LEEP [43,52], recorded no major
short-term complication in any woman.
Cervical stenosis and reproductive outcomes
Out of 6 cryotherapy studies [24,30,32,48,51,54] and 8
LEEP studies [19,33,38-40,47,49,54] (Additional file 4)
that assessed risk of cervical stenosis (typically 6-12
months post-treatment), evidence that such complica-
tion occurred was reported in only 2 LEEP studies (3.3%
and 8.0% of women) [40,47]. Despite the potentially
severe consequences of cervical stenosis, in particular in
premenopausal women, no case definition was provided
in any of the reports. Instead, authors most commonly
used descriptors such as “functional cervical stenosis”,
“clinically apparent stenosis”,o r“complaints consistent
with cervical stenosis”. We found no more than anecdo-
tal data on risks associated with cryotherapy and LEEP
performed during pregnancy and no data on long-term
fertility and pregnancy outcomes.
HIV infection
In a randomized trial [29], the 6-month risk of HIV ser-
oconversion was similar among HIV-negative women
who underwent and did not undergo cryotherapy at
baseline (RR, 1.06; 95% CI, 0.59-1.53), but the authors
noted that the study had only 80% power to detect a
2-fold increase in seroconversion risk. We did not find
any other study that assessed whether women treated
for CIN were at higher risk of acquiring or transmitting
HIV infection. Although data were sparse, there was no
evidence that harms of cryotherapy and LEEP were
more common, or severe, in HIV-infected women com-
pared to HIV-uninfected women [19,33,35,40,53].
Comparisons betweens safety of cryotherapy and LEEP
Only one randomized controlled trial [53] made direct
comparisons betweens adverse outcomes of cryotherapy
and LEEP. Level of pain and frequency of moderate
bleeding during treatment were similar among the 200
women allocated to the cryotherapy arm and the 200
women allocated to the LEEP arm. At two-week follow-
up, however, compared to women treated with cryother-
apy, women treated with LEEP were more likely to report
secondary bleeding (79.0% versus 40.0%; p < 0.001) and
offensive discharge (79.0% versus 68.2%; p = 0.03), and
less likely to report watery discharge (78.5% versus 92.4%;
p < 0.001).
Risk stratification
Few studies attempted to identify risk factors for com-
plications of cryotherapy or LEEP. The factors consid-
ered included pregnancy for cryotherapy [31], and age
[35], histologic grade [35,36], lesion size [35], and num-
ber of treatments for LEEP [35,36]. None of the studies
were sufficiently powered for this assessment, however,
and only repeat LEEP (versus first LEEP) was found to
be associated, in one study, w i t ham a r g i n a l l yi n c r e a s e d
risk of complication (persistent bleeding) [34].
Discussion
Our systematic review of the literature suggests that the
short-term adverse outcomes of cryotherapy and LEEP
for cervical abnormalities p e r f o r m e db yh i g h l ys k i l l e d
providers, or carefully-trained and well-supervised mid-
level providers, in low- and middle income countries do
not differ substantially from the outcomes previously
documented for these procedures in resource-rich coun-
tries. Precise estimates of safety rates associated with
cryotherapy and LEEP in less-developed countries can-
not be determined at this point, however, since informa-
tion remain sparse, and few of the reviewed studies, if
any, met current standards for accurate and comprehen-
sive reporting of harms [23,57,58].
Overall, the high degree of heterogeneity in quality,
reporting, and study results complicated the tasks of
abstracting and summarizing data. Most reports focused
on a narrow array of perioperative and post-intervention
outcomes, and few included any patient-centered mea-
sure, assessment of functional outcomes, or evaluation
of long-term fertility and pregnancy outcomes. In a
majority of reports the description of the data collection
methods was superficial. Typically, the study personnel
simply recorded the complications that they attributed
to treatment; operational definitions of harms were not
provided; and degree of harm was not reported on
explicitly-defined severity scales. A minority of studies
accounted for the possibility that patients experiencing
complications may seek care at a non-study health insti-
tution. Finally, only one study reported information
from a control group of untreated women to account
for background risks [29].
Assumptions about safety of cryotherapy in recent
decision models
In recent years, several decision models have been pro-
posed to compare the cost-effectiveness of a range of
cervical cancer screening protocols in resource-limited
settings [4-6]. In these analyses, minor short-term com-
plications requiring a clinical visit and outpatient
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women undergoing cryotherapy, and more severe com-
plications requiring 1-2 days of hospitalization in 0.5%
to 1% of women. Both our review and the review of the
ACCP [21] suggest that these assumptions were likely to
be conservative.
LEEP safety
In LEEP outcome studies conducted in resource-rich
countries, about 70% of women experienced vaginal dis-
charge for a median of two weeks, typically with light
bleeding during the first few days, and some 40% of
women complained of menstrual-like pain during an
average of three days [59]. Minor complications leading
to patients returning to the clinic for evaluation occurred
in less than 15% of women, and major short-term com-
plications requiring hospitalization, surgery, or both
occurred in no more than 2.0% of women [56,59,60].
Asymptomatic cervical stenosis (i.e., a stenosis revealed
only by the inability to pass a fine probe through the cer-
vical canal) was observed in up to 4%-6% of women
[60,61]. Our findings appear to be of the same order of
magnitude, although few of the studies included in our
review reported on the frequency of complications lead-
ing to outpatient visit or hospitalization.
Although innovative models of referral and manage-
ment services are being tested in resource-limited set-
tings [19], it must be noted that LEEP is still typically
performed by high-level providers in district or provin-
cial facilities. Because the LEEP studies we reviewed
were conducted by highly qualified and well-trained
operators in teaching facilities, it is unclear whether the
favourable results obtained thus far in less-developed
countries will be maintained when screening programs
are scaled up and LEEP is performed in remote areas by
less skilled providers. More generally, it is difficult to
see how the need for surgical providers will be met in
the foreseeable future given the current scarcity of
health resources and the shortage in health care workers
in many part of the world.
Literature gaps
The most substantial knowledge gap is that the safety of
cryotherapy and LEEP has been the least studied in low-
resource settings where the consequences of complica-
tions are potentially more serious. Experience with
cryotherapy and LEEP, in women living with HIV/AIDS
in particular, remains limited. In Africa, prevalence of
CIN in these women reaches 50% to 76% [62,63].
Hence, most programs are likely to adopt aggressive
screening protocols in HIV-infected women and to
monitor HIV-infected women treated for cervical
abnormalities every 6 months for persistent or recurrent
lesions. Given the low efficacy of cryotherapy in women
living with HIV/AIDS [64], there is a risk, in the
absence of adequate quality assurance and performance
feedback, that screening personnel engages in cycles of
increasingly aggressive interventions that result in sub-
stantial cumulative harm without necessarily leading to
meaningful long-term benefit to the patient.
Our systematic review identified only one study that
assessed the risk of a woman becoming infected with
HIV after cryotherapy; none that assessed risk of HIV
infection after LEEP; and none that assessed the risk of
HIV transmission after cryotherapy or LEEP from an
infected woman to an uninfected partner. This is a
major concern given what is known about the role of
genital ulcerative diseases in the transmission of HIV,
the ever-present risk of breeches in the process of
instrument disinfection and sterilization in resource-
deprived settings, and existing evidence that high levels
of HIV-1 are shed in the vaginal secretions of infected
women treated for CIN [65].
Finally, our review did not find any study that assessed
pregnancy outcomes after first or repeated treatments of
cervical abnormalities. This is troubling since HIV-
infected women diagnosed with CIN in sub-Saharan
Africa are generally of reproductive age and living in
societies that allocate a central importance to fulfilling
marital and reproductive goals. Although evidence about
the effects of cryotherapy and LEEP on future pregnan-
cies in high-income countries have been negative or
equivocal [58], the medical literature suggests both that
cervical length at 24-28 weeks of gestation is inversely
related to the incidence of preterm birth [66] and that
cervical length measured by transvaginal ultrasonogra-
phy during pregnancy is reduced after both cryotherapy
and LEEP [67]. In a recent systematic review, pooled
risk of preterm delivery was 2.6 times higher when
depth of resection after LEEP was ≥ 10 mm versus <10
mm [68]. Despite conflicting results, a history of LEEP
has also been found associated in some studies with
increases in risk of preterm birth (<34 - 37 weeks’ gesta-
tion), premature rupture of the membranes, and low
birth weight infants (<2500 g) [58,68,69]. Large studies
are needed to identify the conditions under which
cryotherapy and LEEP can be safely performed in
women of reproductive age living in less-developed
countries.
Strength and limitations
Our systematic review of recent studies of the harms of
cryotherapy and LEEP in developing countries includes
only one study [32] that was discussed in the earlier
report by the ACCP [21]. Our findings should be inter-
preted with caution since source data had substantial
limitations. It appears likely that unpublished studies
were performed with fewer resources and under lower
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Page 8 of 11standards of quality assurance. Hence, even though
negative findings may have remained unpublished, there
is also a possibility that results presented in our review
underestimate the true adverse outcomes of cryotherapy
and LEEP performed under routine conditions in per-
ipheral, resource-deprived, settings.
Conclusions
Our review does not provide evidence that cryotherapy
and LEEP for cervical lesions in low- and middle-
income countries are associated with more frequent, or
more severe, adverse outcomes than in resource-rich
contexts. Our review does indicate, however, that cur-
rent data are insufficient to fully inform decisions on
protocols for cervical cancer screening in HIV-infected
women and women of reproductive age. Safety of CIN
therapy should be further assessed in these populations
under conditions of routine delivery by lower-skilled
providers before screening becomes widely offered out-
side of demonstration programs. Finally, alternatives to
cryotherapy and LEEP are needed. Since recent develop-
ments in the understanding of the HPV life cycle offer
new prospect for identifying targets for drug design
[70,71], research on non-surgical therapies for CIN
should be encouraged.
Additional file 1: Search algorithm in Medline.
Additional file 2: Characteristics of cryotherapy studies, and studies of
cryotherapy versus LEEP, included in the review.
Additional file 3: Characteristics of LEEP-only studies included in the
review.
Additional file 4: Summary of evidence on safety of cryotherapy and
LEEP for CIN in less-developed countries, 1995-2009.
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